First-in-Human Study With GNbAC1 in Healthy Volunteers

Phase 1 Completed 33 enrolled GeNeuro Innovation SAS

RandomizedParallel-groupTriple-blindTreatment

The purpose of this study is to assess the safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects.

Evaluation	Drug	Modality	Dose	Route
Subject	Temelimab	Monoclonal antibody	0.0025 mg/kg	Intravenous
Subject	Temelimab	Monoclonal antibody	0.025 mg/kg	Intravenous
Subject	Temelimab	Monoclonal antibody	0.15 mg/kg	Intravenous
Subject	Temelimab	Monoclonal antibody	0.6 mg/kg	Intravenous
Subject	Temelimab	Monoclonal antibody	2 mg/kg	Intravenous
Subject	Temelimab	Monoclonal antibody	6 mg/kg	Intravenous